Related Experiment Videos
[Amikacin and kanamycin. Comparative experimental studies on nephrotoxicity]
Arzneimittel-Forschung
|January 1, 1978
Summary
Amikacin and kanamycin, common antibiotics, can harm kidneys (nephrotoxicity) even at therapeutic doses. Researchers identified specific toxic thresholds for these drugs in rats, highlighting potential risks for human patients.
Area of Science:
- Nephrology
- Pharmacology
- Toxicology
Background:
- Aminoglycoside antibiotics like amikacin and kanamycin are crucial for treating bacterial infections.
- However, their use is limited by potential kidney damage (nephrotoxicity).
Purpose of the Study:
- To investigate the nephrotoxic effects of amikacin and kanamycin in a rat model.
- To determine the threshold doses for kidney damage at both tubular and glomerular levels.
Main Methods:
- Female Wistar rats received varying doses of amikacin or kanamycin intramuscularly for 5 days.
- Kidney function was assessed by measuring tubular cell and enzyme excretion (MDH, LDH, GOT), serum urea levels, and through histological examination.
Main Results:
- Both amikacin and kanamycin demonstrated dose-dependent tubulotoxicity.
- Higher doses also induced glomerulotoxicity.
- Identified toxic threshold doses: amikacin at 10 mg/kg/day and kanamycin at 5 mg/kg/day, falling within human therapeutic ranges.
Conclusions:
- Amikacin and kanamycin exhibit significant nephrotoxicity in rats.
- The identified toxic thresholds suggest a potential risk of kidney damage in humans at therapeutic dosages.
- Further clinical monitoring is warranted for patients receiving these aminoglycosides.